This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

ACI-35

Johnson & Johnson

Drug Names(s): Anti-phospho-Tau Vaccine, Anti-pTau Vaccine

Description: ACI-35 is a liposomal vaccine.

Deal Structure: AC Immune and Piramal
In May 2014, AC and Piramal announced that they have entered into an exclusive worldwide license agreement for the research, development and commercialization of AC Immunes Tau protein positron emission tomography (PET) tracers supporting the diagnosis and clinical management of Alzheimers disease (AD) and potential Tau-related disorders.

Under the terms of the agreement, AC Immune will receive an undisclosed upfront payment and is eligible for significant milestone payments on products achieving development goals in AD and other Tauopathies. Additionally, AC Immune is entitled to receive tiered royalties on net sales of products resulting from the partnership. AC Immune will work in collaboration with Piramal Imaging to efficiently advance several lead candidates through late pre-clinical radio-pharmacology development. Piramal Imaging will have global rights for clinical development, manufacturing and commercialization of a Tau-PET Tracer...See full deal structure in Biomedtracker

Partners: AC Immune, Ltd.


ACI-35 News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug